The current management of ER+ breast cancer is based on how far the disease has progressed at the time of diagnosis, HER2 status and genomic risk leading to treatments that include chemotherapy, endocrine therapy, and targeted therapy (6). Here, ESR1 is linked to breast carcinoma.